Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210125 · ClinicalTrials.gov registry record · Phase 4
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
A Phase 4 study of HIV, sponsored by Kelley-Ross & Associates.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT07210125: Recruiting Phase 4 study of HIV, sponsored by Kelley-Ross & Associates.
NCT07210125 is a Phase 4 study of HIV that is actively recruiting participants, run by Kelley-Ross & Associates. The registered enrollment target is 75 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07210125, a Phase 4 study of HIV, is actively recruiting participants, sponsored by Kelley-Ross & Associates.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
Primary Outcome
Calculated by dividing the number of participants present in the study at 1 year by the number of individuals enrolled
Conditions Studied
Interventions
- OTHER Standard of Care (SOC)
- DRUG Lenacapavir long-acting
Study Locations (1)
Washington
- Kelley-Ross Pharmacy - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 4 |
What NCT07210125 shows while recruiting
NCT07210125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower).
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care (SOC) is the first listed.
NCT07210125 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07210125 about?
NCT07210125 is a clinical study titled "Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting". This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
What is the current status of trial NCT07210125?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2025-09-16. Estimated completion is 2027-06-30.
What conditions does trial NCT07210125 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT07210125?
The interventions under investigation include: Standard of Care (SOC) (OTHER), Lenacapavir long-acting (DRUG).
Who is sponsoring clinical trial NCT07210125?
This trial is sponsored by Kelley-Ross & Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210125 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07210125's enrollment target sits among peer trials
75 185th of 303 higher than 117 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
-
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI